Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neuroectodermal Tumors, Primitive 2Uterine Neoplasms 1Tuberous Sclerosis 1Perivascular Epithelioid Cell Neoplasms 1Neuroendocrine Tumors 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Angiomyolipoma 1

Interventions

Paclitaxel 7Pemetrexed 3Cisplatin 3Carboplatin 3pembrolizumab 2durvalumab 2adavosertib 2Trastuzumab 2Radiotherapy 2Nivolumab 2FANG vaccine 2Docetaxel 2CP protocol 2Brachytherapy 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1seribantumab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olaparib 1niraparib 1larotrectinib 1ipatasertib 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Neoplasms × dactolisib × Clear all
NCT01290406 2012-06-21

BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Novartis

Phase 2 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡